Relmada's rapid-acting NMDA depression drug expected to fail second Phase 3
Relmada Therapeutics said Wednesday morning that a Phase 3 study testing its major depression drug, REL-1017, is likely to fail, cratering its stock price. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
